Mikhail Blagosklonny and His Dream for the Future

In the field of cancer research one researcher has made it his mission to not only cure the disease but help alleviate both the pain and the cost for patients. In his studies, Mikhail Blagosklonny has focused specifically on the connection between aging and cancer and the correlation between an increased age and likelihood of developing cancerous cells. Blagosklonny works as a professor at Roswell Park Institute as a professor of oncology. He started his professorship at New York Medical College in 2002 and received his medical degree and Ph.D. at First Pavlov State Medical University focusing in experimental medicine and cardiology. Before his move to Roswell, He served as the senior scientist at Ordway Research Institute from 2009. His research has attracted attention across the field of study and has been published in various media outlets such as impactjournals.com. His work has become an inspiration to his peers and students who will continue to build on his work after he is gone. His research in the relationship between oncology and anti aging has shown that certain drugs for cancer treatment are used to protect the healthy cells from damage from either the cancerous cells or the treatment to eradicate the diseased cells. He postulates that TOR signaling, a successful treatment regimen for cancer treatment and designing new drugs for combating cancer could have ground breaking uses in the field of anti aging.

To support his stance Blagosklonny has done extensive research in a variety of fields including, targeted cancer therapy, general traditional cancer therapy, anti aging drug applications, and biogerontology. His work is particularly inspiring because of his hopes for its application. Blagosklonny hopes to develop a treatment for cancer that does not damage the surrounding cells. It would eliminate the dangerous cancerous cells while leaving the healthy cells intact. This would not only help patients with pain and avoiding unnecessary tissue damage but would also lead to increase recovery speeds for the patients because their bodies would still have the necessary healthy tissue and cells to begin regeneration faster.

Financially, Blagosklonny hopes to help make the treatment more affordable. His hope is that cancer treatment will cease to be a luxury for the rich but will become a commonplace practice that will be available to anyone who needs it. Blagosklonny not only continues to develop his own research and advancements but also acts as the chief medical editor for two major medical journals, Cell Cycle and Oncotarget. This platform has helped him inspire many of his peers and students to continue with his research and help realize his dream of affordable cancer treatment that can also be used to alleviate the damage that occurs as a result of aging. His research and advancements in these areas of study have helped usher in a new age of discovery that could very soon see his dreams for a cost effective and painless cancer treatment become a reality for everyone no matter where they are from or what their status in society might be.

Contribution of Mikhail Blagosklonny in field of Oncology research

Mikhail Blagosklonny is the modern scientist who concentrated his career in studying age and cancer. Additionally, he is oncology expert at the Institute of Roswell. He took part in the work of an expert in the Roswell Institute from the year 2009. He graduated from First Pavlov State Medical University where he pursued MD in Internal Medicine.Mikhail Blagosklonny further earned a Ph.D. in Experimental Medicine and Medical College. According to his vast skills in the field of medicine, he became the associate professor of medicine at New York Medical College. He then decided to work as the superior scientist at Ordway Research Institute. His experience in the various areas of research contributed much to him becoming an excellent expert in sphere of research.

Mikhail hard work has earned him a post of becoming the Cell Death and Differentiation editorial board. He has made his theory that relates to the TOR indicating the potential relationship between cancer and the age and suggested treatment by the use of Rapamycin. As a sincere researcher and expert in the field of cancer, he has become the ardent supporter of Rapamycin in the use of cancer treatment. The main reason that has put his research among the best is the different potential that ranges from the cellular and molecular biology.Mikhail as a scientist has marked a real ground in the field of research with his interest in Oncology. He is optimistic that the control of cancer and aging is something that is possible. This has pushed him to put in the records of writing about the aging hyper function theory. Furthermore, he analyses the cell cyclotherapy deeply in his explanation. Furthermore, he tries to put forward an explanation about how cancer can be treated. To him, the approach of cancer treatment is easy as it is indicated in the procedures that show the use of the Rapamycin. In his books and articles, he discusses that the possibility of cancers treatment as opposed to the perception of many.

The ardent love for the research and his determination have put him at the best point of being the best-known researcher in the universe. His ambition as a humanitarian is to create a disease free world that is defined by hopefulness in the community. He is also the editor for PLOS ONE; his hard work has placed his achievement at the require niche in the Oncology research.His contribution to cancer and aging has pushed for the in-depth research and how to utilize the use of the Rapamycin in the cancer treatment. His extended study of the signal transduction pathways in the cancer is to target to slow down the disease that related to the aging. This will create a concept that will become a unique in the cancer biology and on the matters that are associated with the therapy. Furthermore, his research will facilitate the new anti-cancer strategies for the best methods of treating the disease and protecting the healthy cells from the effects of the chemotherapy.